Singapore markets closed

Repare Therapeutics Inc. (RPTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.9600+0.0200 (+0.51%)
As of 02:16PM EDT. Market open.

Repare Therapeutics Inc.

7171 Frederick-Banting, Building 2
Suite 270 St-Laurent
Montréal, QC H4S 1Z9
857 412 7018

Full-time employees179

Key executives

NameTitlePayExercisedYear born
Mr. Lloyd Mitchell SegalPresident, CEO & Director932.18kN/A1964
Mr. Steve ForteExecutive VP & CFO632kN/A1979
Dr. Maria Koehler M.D., Ph.D.Executive VP & Chief Medical Officer693.28kN/A1957
Dr. Daniel Durocher Ph.D.Co-FounderN/AN/AN/A
Dr. Frank Sicheri Ph.D.Co-FounderN/AN/AN/A
Dr. Agnel Sfeir Ph.D.Co-FounderN/AN/AN/A
Dr. Michael Zinda Ph.D.Executive VP & Chief Scientific Officer641.53kN/A1971
Mr. Daniel BelangerExecutive Vice President of Human ResourceN/AN/AN/A
Mr. Cameron Black Ph.D.Executive Vice President of DiscoveryN/AN/AN/A
Mr. Philip HermanExecutive VP, Chief Commercial & Portfolio Development OfficerN/AN/A1980
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase I/Ib clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; with Foundation Medicine, Inc. for the provision of prospective genomic profiling of lunresertib alone or in combinations in genomically-defined patient populations; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

Corporate governance

Repare Therapeutics Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.